Xencor (XNCR) Earning Somewhat Positive Press Coverage, Study Shows
News headlines about Xencor (NASDAQ:XNCR) have been trending somewhat positive recently, Accern reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Xencor earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.5160897511527 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news stories that may have impacted Accern’s rankings:
- Xencor Presents Final Results from Phase 2 Study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) at the American College of Rheumatology 2017 Annual Meeting (finance.yahoo.com)
- Xencor, Inc. (XNCR) Receives Consensus Rating of “Hold” from Analysts (americanbankingnews.com)
- Xencor, Inc. (XNCR) Major Shareholder Buys $271,397.00 in Stock (americanbankingnews.com)
- John S. Stafford III Purchases 50,000 Shares of Xencor, Inc. (XNCR) Stock (americanbankingnews.com)
- Xencor to Host Third Quarter 2017 Financial Results Webcast and Conference Call on November 7, 2017 (finance.yahoo.com)
Several analysts have commented on the stock. Canaccord Genuity restated a “buy” rating and set a $36.00 target price on shares of Xencor in a report on Tuesday, August 8th. ValuEngine upgraded shares of Xencor from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Zacks Investment Research downgraded shares of Xencor from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Finally, BidaskClub downgraded shares of Xencor from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Three analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company’s stock. Xencor has a consensus rating of “Hold” and a consensus price target of $28.67.
Shares of Xencor (XNCR) traded up $0.92 on Friday, hitting $20.21. 132,782 shares of the stock traded hands, compared to its average volume of 169,708. Xencor has a one year low of $18.55 and a one year high of $29.38.
Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.10. Xencor had a negative net margin of 121.04% and a negative return on equity of 13.79%. The company had revenue of $13.34 million during the quarter, compared to the consensus estimate of $8.15 million. equities research analysts predict that Xencor will post -1.07 earnings per share for the current fiscal year.
In related news, major shareholder John S. Stafford III acquired 25,000 shares of the firm’s stock in a transaction on Wednesday, August 16th. The stock was bought at an average price of $20.96 per share, for a total transaction of $524,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder John S. Stafford III acquired 27,000 shares of the firm’s stock in a transaction on Friday, August 11th. The stock was bought at an average price of $21.13 per share, with a total value of $570,510.00. The disclosure for this purchase can be found here. Insiders acquired 453,904 shares of company stock valued at $9,102,120 in the last 90 days. 4.03% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: This story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/xencor-xncr-earning-somewhat-positive-press-coverage-study-shows/1680750.html.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.